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Abstract
Background: The introduction of deep brain stimulation (DBS) about 25 years ago provided one of the major
breakthroughs in the treatment of Parkinson’s disease (PD). However, a high percentage of patients are reluctant to
undergo DBS. Previous research revealed that the critical step on the patient’s path to DBS is the decision whether
to undergo further diagnostic assessment for surgery at a specialized DBS-center. The aims of the current study
were to evaluate how effective the combination of an outpatient DBS screening tool, STIMULUS, with specially
developed educational material was to enhance patient education on DBS and to identify motivational aspects
which influenced the patients’ willingness to undergo further assessment.
Methods: In total, 264 patients were identified as appropriate candidates for DBS by general neurologists using the
electronic preselection tool STIMULUS. Patient-centered information material was designed and handed out to
support education on DBS. Further, several clinical characteristics and details of the patient counseling were
documented. Refusal or consent to show up at a DBS center was registered over the following 16 months.
Results: 114 (43.2%) patients preselected as eligible for DBS (STIMULUS Score≥ 6) agreed to show up at a specialized
DBS center to undergo further diagnostic assessment. The patients’ ages, PD classification as an akinetic-rigid type and
the talks’ topics side-effects of dopaminergic medication and the optimal time frame had a significant influence on the
patients’ decisions.
Conclusions: The combination of preselection tools as STIMULUS with comprehensive information material is effective
to increase DBS-acceptance rate in PD patients. Important topics of the information about DBS cover the optimal time
frame for DBS surgery, the side-effects of dopaminergic medication as well as side-effects and complications of DBS
surgery.
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Background
Chronic DBS is a well-tolerated, beneficial and widely estab-
lished treatment for Parkinson’s disease [1, 2]. The selection
process usually consists of two steps: A general neurologist
preselects the patients and refers them to a specialized DBS
center which takes the final decision for or against surgery
based on comprehensive diagnostic assessment.
Bearing in mind that the risk of surgery rises with age
while the benefit tends to decrease [3, 4], the right tim-
ing for a recommendation to undergo DBS treatment is
crucial and merely depends on the evaluation by the
general neurologist. Nevertheless, the decision seems to
be a struggle for general neurologists as only 48 to 55%
of the patients initially referred to DBS centers were later
assessed as appropriate candidates for surgery [5, 6]. In
order to support the preselection, Moro and colleagues
developed an online screening tool called STIMULUS [7].
This tool aids the general neurologists in the referral of
patients with a range of registered demographic and
clinical parameters. The application of STIMULUS
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could decisively improve the preselection process as
77% of referred patients were later assessed as appro-
priate candidates by the DBS center [6].
Despite the high accuracy for preselection, this study
raises another issue: After 6 months, only 28% of patients
with referral as recommended by STIMULUS actually
showed up at the DBS center, mainly due to patients’
reluctance to undergo surgery [6]. During further as-
sessment in the DBS center, only 6% of patients were
excluded for reasons such as poor motivation [6].
The need for patient information provided by profes-
sionals is highlighted by a questionnaire study, addressing
the attitude of Parkinson patients and their relatives to-
wards DBS [8]. The study suggests that the main factors
leading to refusal were unrealistic doubts and mixed ex-
pectations of this treatment [8], as a result of insufficient
information provided predominantly by the media or
other patients [8, 9].
Methods
The aim of the CARE Monitor study was to improve pa-
tient education for DBS and to identify key factors that in-
fluence the patients’ decision to undergo further diagnostic
assessment at a specialized DBS-center. For this purpose,
51 general neurologists located all over Germany were
trained on how to operate the STIMULUS screening tool
and to use a newly developed information material. Ap-
proval from the ethics committee of the Heinrich Heine
University, Düsseldorf was obtained (N: 4641). All data
were collected anonymously.
Construction of the information material
Based upon patients’ doubts and expectations as revealed
by a questionnaire study [8], a comprehensive information
booklet was developed to support physicians in educating
the patients about DBS. In 26 pages, the benefits, risks
and right timing of DBS as well as its procedure for Par-
kinson’s disease are described. A DVD was attached to the
booklet, including a 4-minute film illustrating the DBS
procedure for treating Parkinson’s disease. The German
version of the booklet as well as the film are available at
http://www.medtronic-caremonitor.de.
Data collection
In the following, patients with a STIMULUS score from
6 to 9 were identified as promising candidates for DBS
by general neurologists. Figure 1 illustrates the preselec-
tion process. In total, general neurologists registered 346
patients from January 2010 to May 2012. From these ini-
tial reports, 264 (age 63.7 ± 9.5, 92 female) patients met
the criteria as promising candidates for DBS and were
therefore included in the study. These patients were
Fig. 1 Illustration of the screening and preselection process. 264 patients were preselected as promising candidates for neurostimulation and
thus included in the current study. Finally, 114 (43.2%) of 264 preselected patients consented to referral to a specialized DBS-center to undergo
further diagnostic examinations
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recommended for referral to a DBS-center to undergo
further diagnostic assessments and were comprehen-
sively informed about this treatment, supported by the
newly developed information material. The general
neurologists were free to choose the topics dealt with
during patient counseling but were asked to document
these by filling out a questionnaire. In addition, several
patients’ data, such as age, gender, their disease charac-
teristics and the role of the information material were
recorded. For an English version of the questionnaire,
see the Additional file 1.
Data analyzation
In view of the exploratory nature of our study, we de-
cided to perform a stepwise approach to identify the pre-
dictive factors leading to patients’ consent. First, Mann-
Whitney U tests (for ordinal and scaled data), Chi-Square
tests (for nominal data with more than two categories)
and Fisher’s exact tests (for nominal data with two cat-
egories) were applied to identify candidate variables with a
potential influence on patients’ decisions. Subsequently,
variables with a significant relationship to patients’ deci-
sions (p < 0.05) were stated as candidate variables and thus
included in a stepwise binary logistic regression. For cat-
egorical data, dummy variables were created. Due to this
stepwise approach, we could ensure that at least ten out-
come cases were provided for each predictor variable [10].
All analyses were conducted using IBM SPSS Statistics 22
(International Business Machines Corporation, Armonk,
USA).
Results
Within 16 months of the initial consultation visit, 114
(43.2%) out of 264 preselected patients (STIMULUS
Score ≥ 6) consented to show up at a specialized DBS
center. The newly designed information material was
well accepted and stated to be “helpful” by 156 (78.4%)
patients (“uncertain” n = 28, 14.1% “not helpful” n = 15,
7.5%, n = 65 missing values). Accordingly, the patients’
evaluation of the information material had a highly sig-
nificant correlation with patients’ decisions (p < 0.001).
For a comprehensive overview of all analyzed vari-
ables see Table 1. In total, eleven variables were iden-
tified as promising predictors of patients’ decisions
and therefore underwent binary logistic regression ana-
lysis. These were: patients’ age, Parkinson subtype (akin-
etic‐rigid, tremor‐dominant or equivalent), the total
number of topics addressed during the patient counseling
and the following contents of the counseling talk: motor
improvement, quality of life, side-effects of medication,
optimal time frame, evidence of DBS, other topics. Due to
the high number of missing values (n = 65, 24.6%) pa-
tients’ evaluations of the information material were not in-
cluded in the regression model.
The resulting regression model covering 262 cases
(two cases were excluded due to missing age documen-
tation) explained 20.5% of the variance (Nagelkerke R2, a
medium effect according to a common classification
[11], Χ2 = 43.5, p < 0.001) and correctly classified 68.7%
of all cases. The following four variables significantly im-
proved the predictive value of the regression model on
patients’ decision (p < 0.05) and were therefore part of
the resulting model: age, classification as an akinetic-
rigid type as well as the talk contents dealing with the
“side-effects of medication” and “optimal time frame”.
None of the other variables could significantly improve
the determination of variance and thus were not included
in the regression model. For the p values and odds ratios
of the variables included in the regression model, see
Table 2.
Discussion
Poor consent to undergo DBS surgery is one of the major
problems of this treatment, as only 28% [6] of Parkinson
patients consented in the referral to a specialized DBS-
center, even after being preselected as promising candidates
for this treatment. Thus, a large majority of patients were
not reached to undergo a potentially beneficial treatment.
The resulting regression model of our study suggests
that the consultation visit to provide information on
DBS plays a key role in patients’ decisions, whereas the
disease severity as evaluated by the Hoehn & Yahr Stages
or subjective impairment as well as the clinical eligibility
for DBS measured by the STIMULUS score do not. Of
the various topics that could be addressed, the fact that,
whether or not the side-effects of dopaminergic medica-
tion and the optimal time frame for DBS (meaning rising
risks in surgery with age while benefits decrease [3, 4])
were mentioned in the patients’ education had the great-
est predictive value for patients’ consent. The relevance
of right timing is supported by the significant predictive
value of the patient’s age as the rate of consent decreased
with age. Interestingly, mentioning negative aspects of
DBS during the consultation visit, such as the risks and
complications of the surgery or side-effects of the stimula-
tion, had no negative effect on patients’ approval, even in
our exploratory initial analysis without a correction for
multiple comparisons (see Table 1). Descriptively, a slight
trend towards higher approval after mentioning these fac-
tors could be noted-a hint, that overdrawn fears of pa-
tients are a greater problem than unrealistic expectations,
as described in a previous survey [8]. Therefore, we highly
recommend that negative aspects of DBS should not be
avoided with the intent to not frighten patients. This
should rather be an obligatory topic to be addressed dur-
ing the education for DBS, not least for ethical reasons.
In our study, patients with an akinetic-rigid subtype of
Parkinson’s disease had a significantly higher likelihood
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Table 1 Correlation between patients’ consent to be referred to a DBS center, clinical characteristics and the contents of clarification
sessions
Group Consent Group Refusal
N = 114 (43.2%) N = 150 (56.8%)
N Median 25./75. Quartiles Median 25./75.Quartiles p*
Numerical Data
Age 262 63 53–70 67 60–71 0.002
Disease duration 245 9 5–12 8 6–12 0.618
Hoehn & Yahr Stage 250 3 2–3 3 2–3 0.995
Eligibility for DBS (STIMULUS Score) 260 8 7–9 8 7–9 0.682
Subjective Impairment 255 7 6–8 7 6–8 0.178
Number of topics addressed in the
clarification talk
264 6 4–9 5 3–9 0.001
Categorial Data N % N % p*
Gender Male 73 64.0 99 66.0 0.795
Female 41 36.0 51 34.0
Occupation Working 21 18.4 17 11.3 0.362
Retired 79 69.3 118 78.7
Unemployed 13 11.4 14 9.3
Subtype Akinetic-rigid 45 39.5 33 22.0 0.008
Tremor dominant 21 18.4 38 25.3
Equivalent 48 42.1 79 52.7
Evaluation of the information
material
Helpful 79 89.8 77 69.4 <0.001
Uncertain 8 9.1 20 18.0
Not helpful 1 1.1 14 12.6
Information source‡ Media 4 3.5 9 6.0 0.265
Doctor 93 81.6 117 78.0 0.539
Support group 3 2.6 8 5.3 0.360
Others 1 0.9 1 0.7 >0.999
Patient with DBS 3 2.6 0 0.0 0.079
Contents of clarification talk‡ motor improvement 104 91.2 117 78.0 0.004
quality of life 106 93.0 114 76.0 <0.001
side effects of medication 86 75.4 76 50.7 <0.001
optimal time frame 66 57.9 50 33.3 <0.001
expectations 60 52.6 62 41.3 0.081
change of role model in partnership 20 17.5 25 16.7 0.870
patients fears 20 17.5 20 13.3 0.388
evidence of DBS 44 38.6 34 22.7 0.006
experience with DBS 43 37.7 54 30.0 0.191
complications of DBS surgery 63 55.3 74 49.3 0.385
side effects of DBS 58 50.9 63 42.0 0.171
effects of medication withdrawal 32 28.1 39 26.0 0.780
progression of PD 52 45.6 58 38.7 0.260
others 16 14.0 9 6.0 0.034
* To analyze the impact of numerical data on patients’ decisions, Mann-Whitney U tests were calculated and the median and 25.-75. quartiles are presented. For
categorial variables with more than two categories (subtype and occupation) Chi-Square tests were conducted. For categorial variables with two categories, Fish-
er's exact tests were conducted. Exact two-tailed p values are presented. A variable with a p value < 0.05 was considered as a potential predictive variable and
therefore included in the binary regression analysis.
‡ In the categories information source and contents of clarification talk more than one option could be reported. Therefore, Fisher's exact tests were calculated for
the prevalence or absence of each topic/source and the resulting p values are presented. To clarify the presentation only the number of prevalent cases
are shown.
The entries in italicized represent significant p values (lower than 0.05)
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to consent to the referral to a DBS-center, despite re-
cently published evidence indicating higher benefit of
DBS for other subtypes, such as the tremor dominant
[12]. Possibly, akinetic-rigid patients are in greater need
for alternative treatments as the prevalence of this sub-
type contributes to a poorer quality of life [13]. On the
other hand, we were not able to find a relationship be-
tween the patients’ subjective impairment and their de-
cisions. However, we cannot completely rule out a
mediating effect of the patients’ quality of life as we
did not apply a conventional measurement of quality
of life such as the PDQ-39 assessment.
An ongoing discussion addresses the common finding
that approximately twice as many men are recipients of
DBS than women [14, 15] even though epidemiology
studies suggest an equal distribution of Parkinson’s dis-
ease [16, 17]. With regard to clinical eligibility for DBS,
no gender differences were found, suggesting that non-
biological factors may be accountable for this prominent
gender discrepancy in DBS recipients [18]. Setiawan and
coworkers proposed that women may have more doubts
or fears regarding DBS [15]. In line with previous results,
the current study could reproduce the typical gender dis-
tribution as only 92 (34.8%) women were preselected as
eligible candidates for DBS. In contrast to Setiawan and
colleagues’ assumption, the patients’ genders were not re-
lated to their decision to undergo DBS. Hence, the reasons
for the gender distribution of parkinsonian patients under-
going DBS remain unclear.
In our study, 31.8% of the patients consented to the
referral within the first 6 months after the initial screen-
ing, the same time interval as in Wächter and colleagues’
trial [1] (see Additional file 2:Figure S1). Although this
ratio indicates only a slight increase of approval with the
usage of information material, it probably underestimates
its effect. The current study was designed to follow the pa-
tients’ decision for 16 months and the participating neu-
rologists were therefore not obliged to report consent
within the first 6 months. In the total 16-month period of
the study, 114 (43.2%) of the 264 patients who were prese-
lected as eligible for DBS consented to show up at a spe-
cialized DBS-center. Therefore, our data indicates that
adequate training of general neurologists and support with
information materials for patients and their relatives can
increase the rate of approval for DBS treatment. This as-
sumption is supported by the high correlation of patients’
evaluation of the information material to their decisions
(see Table 1). Accordingly, our data emphasize the useful-
ness of information materials such as booklets or DVDs as
an effective and low-cost method to support the patient
counseling for DBS.
Even though our data clearly indicate a strong rele-
vance of the patient information, no causal connections
can be deduced because our study is lacking a control
group receiving no or reduced information about DBS.
Further, our data only cover a German cohort and thus
should be interpreted with caution regarding other
health-care systems.
Conclusions
Adequate patient education by general neurologists is fun-
damental to allay patients’ aversion to DBS and should
cover the optimal time frame to undergo surgery as well
as dopaminergic side-effects which could be avoided by
DBS treatment. Negative aspects of this therapy should
not be evaded and are an obligatory topic in any ethical
clarification session. Specialized, patient-centered infor-
mation material provides a low-cost and effective way to
additionally support education about DBS.
Additional files
Additional file 1: English Version of the Questionnaire. This questionnaire
was used to collect all patients’ characteristics and the informative talks’
contents that could be of potential relevance for patients’ decision to
undergo further diagnostic assessment in a specialized DBS center. This
questionnaire was handed out to 51 general neurologists located all over
Germany to track patients’ decisions for 16 months following an initial
patient briefing on DBS. (DOC 48 kb)
Additional file 2: Figure S1. Patients’ rate of consent in the course of
time. Percentage of patients who consented in the referral after follow-up
intervals of up to 16 months. Descriptively, more than a half (n = 60) of all
consenting patients underwent further diagnostic examinations within the
first 3 months after initial referral was suggested. This emphasizes the key
role of the informative talk. Afterwards, the gradient of the acceptance rate
tends to stabilize. (PNG 18 kb)
Table 2 Coefficients of the predictive regression model
Odds ratio† 95% Confidence Interval p
Age 0.96 0.93 0.98 0.002
Akintetic-rigid type 2.32 1.29 4.15 0.005
Clarification talk contents
optimal time frame 2.24 1.28 3.94 0.005
side effects of medication 2.22 1.23 4.0 0.008
Table 2 summarizes the variables which significantly increased the predictive value of the resulting regression model.
† Odds ratios compare patients who consented with patients who failed to show up at a DBS-center. As an example, the Odds ratio of 2.32 indicates that the
chance of a “consent” patient having an akinetic-rigid subtype is 2.32 times higher than the chance of a “refuser”
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